A new study indicates that protein kinases, which initiate the process that erodes the body’s immunity, significantly contribute to the immunodeficiency in HIV patients.
Drugs that block these protein kinases may offer a solution to treating HIV patients whose immunity is not restored by antiretroviral therapy.
HIV infections are treated with antiviral drugs which effectively prevent the disease from developing. While pharmacological HIV therapy has advanced considerably, the virus cannot be entirely eliminated from the body with currently available drugs.
However, in roughly one-fifth of HIV patients the immune system does not recover as expected: the quantity of CD4 T cells, reflecting the status of the immune system, remains low even when the quantity of HI viruses in blood is suppressed to very low levels or below the measurement threshold.
In such patients, indications of chronic immune activation, which erodes the immune system, can be detected.
In cooperation with the University of Erlangen-Nuremberg in Germany, researchers at the University of Helsinki have already shown that the Nef protein, a central factor associated with the HI virus, can continue low-level production in the patient’s tissues for a long time even after viral multiplication is successfully suppressed.
Important to this immunity-eroding activity are extracellular vesicles generated by Nef, circulating in blood and promoting chronic immune activation.
In a new study, Professor Kalle Saksela’s research group has discovered an intracellular mechanism through which the chain of events associated with immune activation is initiated.
The study was published in the Journal of Virology.
“The new findings demonstrate that the Nef protein kicks off this harmful chain of events via cellular signaling: it activates protein kinases of the Src family, which leads to the activation of Raf and MAPK protein kinases. As these two protein kinases are activated, the production of extracellular vesicles, mediated by them, begins,” Saksela explains.
Protein kinase inhibitors as a new treatment option?
Pharmaceutical agents that inhibit Src, Raf and MAPK protein kinases are already in clinical use, and the researchers at the University of Helsinki investigated their utility as well.
Studying the drugs in tissue cultures, they observed that it was possible to entirely prevent the production of inflammatory extracellular vesicles caused by the Nef protein using the same drug levels as in the current clinical use of protein kinase inhibitors.
“Our findings make it possible to explore novel therapies without delay in patients whose immunodeficiency is not reversed to a sufficient degree with current antiretroviral therapies. The repurposing of kinase inhibitors for treating HIV infection appears to be a very promising way of solving this significant medical challenge,” Professor Saksela states.
In recent years, roughly 150 new HIV infections have been diagnosed in Finland annually. Throughout the 2000s, the number of new infections per year has remained under 200. In 2018 approximately 38 million people were estimated to be HIV positive, most of them in Africa.
Epigenetic changes are known as heritable changes in gene expression without underlying changes in the encoding DNA sequence and are influenced by external environmental factors. Epigenetic changes include DNA methylation and histone modifications . DNA methylation is a covalent modification that occurs on cytosine (C) residues, mostly those located in CG dinucleotides (CpGs), by means of a reaction catalysed by DNA methyltransferases (DNMTs).
DNMTs are responsible for maintaining methylation, in which a methyl group is transferred from S-adenyl methionine (SAM) to the fifth carbon of a C residue to form 5-methylcytosine (5mC) . However, the nervous system is a complex biological system in which cell differentiation into diverse lineages occurs as a result of tissue-specific methylation patterns .
Moreover, ten eleven translocation (TET) enzymes oxidize 5mCs and promote locus-specific reversal of DNA methylation. An estimated ∼2–8% of the total cytosines in human genomic DNA are 5mCs, suggesting that epigenetic modification of the 5mC level may impact a broad range of biological functions including neuronal differentiation, neural plasticity, and brain functions .
Human immunodeficiency virus (HIV) is known for its high evolutionary potential, mutation rate and rapid turnover upon infection in a human host . HIV targets immune cells, and the viral genome assumes control over the cellular machinery and ultimately affects the central nervous system (CNS) .
HIV infection alters redox changes, mitochondrial biogenesis and epigenetic modifications, including DNA methylation, which regulates gene expression cascades in humans [8–10]. Trans-activator of transcription protein (Tat), which has a length of 86–102 amino acids (aa), is a viral protein secreted from HIV-infected cells and is known to control HIV transcription . HIV-1 Tat is known to disrupt cellular homoeostasis and induce oxidative stress that leads to reactive oxygen species (ROS) accumulation, which can further alter CNS functions [12,13].
Studies have shown that HIV-1 Tat activates epigenetic modification in the animal brain  as well as mouse primary microglia . HIV-1 Tat affects energy deficits in astrocytes and impairs mitochondrial functions, leading to cell death . Mouse model studies have shown that exposure to HIV-1 Tat not only affects the membrane potential  but also alters mitochondrial functions .
Moreover, HIV-1 Tat affects mitochondrial dynamics by disrupting the functions of fission and fusion proteins, ultimately causing damage to mitochondrial DNA (mtDNA) and proteins [19,20]. HIV-1 Tat exposure-mediated mtDNA damage induces genetic changes in immune cells [21,22]. Additionally, studies have documented that mtDNA mutations are associated with various CNS-related disorders, including ataxia, seizures and dementia .
These effects are commonly associated with biochemical defects in oxidative phosphorylation (OXPHOS) related to seven subunits of complex I (NADH dehydrogenases 1–6 [ND1–6] and ND4L), three subunits of complex IV (cytochrome c oxidase subunits I–III [COX1–3]), two subunits of complex V (ATPase 6 and ATPase 8), and one subunit of complex III (cytochrome b) .
The psychostimulant drug cocaine has been shown to affect the CNS in a number of manners, such as by significantly impairing cellular functions, in both in vitro and in vivo studies [25,26]. Clinical studies have also demonstrated that cocaine increases oxidative stress, inflammation and mitochondrial biogenesis, which can cause brain damage [27,28]. Alterations in mitochondrial function are known to impact fission, fusion and oxidation, which are mediated by mtDNA [29,30].
Recent in vitro, in vivo and clinical studies have shown that cocaine alters several cellular functions, including mitochondrial biogenesis and epigenetic modification of DNA methylation [31,32]. Notably, these activities are accelerated by the presence of HIV infection .
Moreover, studies have shown that cocaine abuse and addiction can compromise judgement and decision-making power, which may increase the risk of HIV infection . Furthermore, cocaine abuse induces oxidative stress and ROS production, which may affect mtDNA and thus impact mitochondrial functions, including oxidative phosphorylation (OXPHOS).
reference link: https://www.tandfonline.com/doi/full/10.1080/15592294.2020.1834919
Protein kinases and phosphatases are enzymes catalysing the transfer of phosphate between their substrates. A protein kinase catalyses the transfer of γ-phosphate from ATP (or GTP) to its protein substrates while a protein phosphatase catalyses the transfer of the phosphate from a phosphoprotein to a water molecule.
Even though both groups of enzymes are phosphotransferases, they catalyse opposing reactions to modulate the structures and functions of many cellular proteins in prokaryotic and eukaryotic cells. Among the various types of posttranslational modifications, protein phosphorylation and dephosphorylation are the most prevalent modifications regulating the structures and functions of cellular proteins in a wide spectrum of cellular processes, ranging from cell fate control to regulation of metabolism.
For example, even though protein kinase genes constitute only 2% of the genomes in most eukaryotes, protein kinases phosphorylate more than 30% of the cellular proteins . Owing to the significant roles of protein kinases and phosphatases in cellular regulation, this special issue focuses on their regulation, and functions.
In this issue, there are two research articles and seven reviews on various topics related to the structure, regulation and functions of protein kinases and phosphatases. Together, they give the readers a glimpse of the roles played by protein kinases and phosphatases in regulating many physiological processes in both prokaryotic and eukaryotic cells. They also highlight the complexity of the regulation of protein kinases and phosphatases.
Phosphorylation regulates protein functions by inducing conformational changes or by disruption and creation of protein-protein interaction surfaces [2, 3]. Conformational changes induced by phosphorylation are highly dependent on the structural context of the phosphorylated protein. Upon phosphorylation, the phosphate group regulates the activity of the protein by creating a network of hydrogen bonds among specific amino acid residues nearby.
This network of hydrogen bonds is governed by the three-dimensional structure of the phosphorylated protein and therefore is unique to each protein. The most notable example of regulation of protein function by phosphorylation-induced conformational changes is glycogen phosphorylase . Glycogen phosphorylase, made up of two identical subunits, is activated upon phosphorylation of Ser-14 of each subunit by phosphorylase kinase .
Phosphorylation of Ser-14 in one monomer creates a network of hydrogen bonds between the phosphate group and the side chains of Arg-43 of the same monomer as well as Arg-69 of the other monomeric subunit . This network induces significant intra- and intersubunit configurational changes, allowing access of the substrates to the active sites and appropriately aligning the catalytically critical residues in the active sites for catalysis of the phosphorolysis reaction.
Phosphorylation can also modulate the function of a protein by disrupting the surfaces for protein-ligand interactions without inducing any conformational changes. For example, phosphorylation of Ser-113 of the bacterial isocitrate dehydrogenase almost completely inactivates the enzyme without inducing any significant conformational changes [6, 7].
The phosphate group attached to Ser-113 simply blocks binding of the enzyme to isocitrate. Likewise, phosphorylation can also create ligand-binding surface without inducing conformational changes. For example, tyrosine phosphorylation of some cellular proteins creates the binding sites for SH2 domains and PTB domains [8, 9].
The functions of protein kinases and phosphatases are mediated by their target substrates. Understanding how protein kinases and protein phosphatases recognise their respective substrates is one of the methods used by various investigators to elucidate the physiological functions of these important enzymes. Before completion of the human genome project, most protein kinases were discovered after the discoveries of their physiological protein substrates.
The most notable example is phosphorylase kinase which was discovered after glycogen phosphorylase was discovered to be regulated by phosphorylation. However, in the postgenomic era, the genes encoding protein kinases and phosphatases of an organism are known upon completion of the genome project. The challenge now is to identify their physiological protein substrates.
Protein kinases employ two types of interactions to recognize their physiological substrates in cells: (i) recognition of the consensus phosphorylation sequence in the protein substrate by the active site of the protein kinase and (ii) distal interactions between the kinase and the substrate mediated by binding of docking motif spatially separated from the phosphorylation site in the substrate and interaction motif or domain located distally from the active site of the kinase [1, 10].
These interactions contribute to the ability of protein kinases to recognize their protein substrates with exquisite specificity. Defining the structural basis of these interactions is expected to benefit identification of potential physiological substrates of protein kinases. Relevant to this, the orientated combinatorial peptide library approach developed in the 1990s and the more recently developed positional scanning peptide library approach allow rapid determination of the optimal phosphorylation sequence of many protein kinases [11, 12].
Notably, Mok et al. reported using this approach to define the optimal phosphorylation sequences of 61 out of 122 protein kinases encoded by the Saccharomyces cerevisiae genome . Scanning the proteomes for proteins that contain motifs similar to the optimal phosphorylation sequence of a protein kinase will assist the identification of potential physiological substrates of the kinase .
Armed with the knowledge of many known three-dimensional structures of protein kinases with the peptide substrate bound to the active site, Brinkworth et al. designed the PREDIKIN program capable of predicting the optimal phosphorylation sequence from the primary structure of a protein serine/threonine kinase [14, 15].
Besides the peptide library approaches, researchers can also search for cellular proteins in crude cell or tissue lysates that are preferentially phosphorylated by a protein kinase in vitro. This method, referred to as “kinase substrate tracking and elucidation (KESTREL)” has led to the identification of potential physiological protein substrates of a number of protein kinases .
Finally, using specific synthetic small-molecule protein kinase inhibitors, researchers were able to perform large-scale phosphoproteomics analysis to identify physiological protein substrates of a specific protein kinase in cultured cells .
Substrate specificity of protein phosphatases is governed by interactions between interaction motifs or domains located distally from the phosphatase active site and distal docking motifs spatially separated from the target phosphorylation sites in protein substrates [17, 18].
Little is known about the role of the active site-phosphorylation site interactions in directing a protein phosphatase to specifically dephosphorylate its protein substrates. Using the oriented phosphopeptide library approach, several groups of researchers were able to define the optimal dephosphorylation sequences of several protein tyrosine phosphatases [19, 20], suggesting the active site-phosphorylation site interactions also play a role in dictating the substrate specificity of protein tyrosine phosphatases. Finally, the substrate-trapping mutant approach pioneered by Flint et al. in the last decade has allowed identification of physiological protein substrates of many phosphatases .
In this special issue, the two research articles focus on how pyruvate dehydrogenase kinase and Akt recognise their physiological substrates. The article by T. A. Hirani et al. explores how pyruvate dehydrogenase directs its recognition and phosphorylation by pyruvate dehydrogenase kinase.
The article by R. S. Lee et al. reported results of their investigation that aims to decipher the regulatory mechanism governing substrate specificity of the various isoforms of Akt. The review article by A. M. Slupe et al. focuses on the structural basis governing how protein phosphatase 2A recognises its physiological substrates in cells.
It is well documented that aberrant regulation of protein kinases and phosphatases contributes to the development of diseases. For example, constitutive activation of many protein tyrosine phosphatases is known to cause cancer and neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases.
Protein kinases and phosphatases are regulated by protein-protein interactions, binding of ligands, and reversible or irreversible covalent modifications such as phosphorylation and limited proteolysis. In this special issue, the article by I. Nakashima et al. summarizes how protein tyrosine kinases are regulated by redox reactions. C. F. Dick et al. reviewed how the activity of protein and acid phosphatases in yeast, plants, and other microorganisms is regulated by inorganic phosphate.
Among the cellular processes in which protein kinases and phosphatases are involved, this issue contains review articles detailing how protein kinases and phosphatases regulate cell cycle, mediate toll-like receptor signaling, and control of cell fate and potassium channel and intracellular calcium concentration in renal tubule epithelial cells.
In addition to protein phosphatases, acid phosphatases are involved in regulation of many biological processes such as an organism’s adaptation to stress and hydrolysis of phosphorylcholine. This issue contains three review articles on the function, catalytic mechanism, and regulation of this important group of phosphatases.
Heung-Chin Cheng Heung-Chin Cheng
Robert Z. Qi Robert Z. Qi
Hemant Paudel Hemant Paudel
Hong-Jian Zhu Hong-Jian Zhu
reference link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3238372/#:~:text=Protein%20kinases%20and%20phosphatases%20are,phosphoprotein%20to%20a%20water%20molecule.
More information: Zhe Zhao et al. HIV-1 Nef-induced secretion of the proinflammatory protease TACE into extracellularvesicles is mediated by Raf-1, and can be suppressed by clinical protein kinase inhibitors, Journal of Virology (2021). DOI: 10.1128/JVI.00180-21